Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

The time interval between onset of interstitial lung disease (ILD) and diagnosis of anti–melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) "has not been well ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

When breathing becomes a daily battle, even the simplest acts can feel exhausting. Now, a new study has found the key to easing chronic breathlessness caused by lung disease: singing. Chronic ...

Antifibrotic therapy improves survival in PF-ILD patients, but not universally in all PPF cases, highlighting PPF heterogeneity. The "despite management" criterion helps identify patients who benefit ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Patients with systemic autoimmune rheumatic disease who develop interstitial lung disease ...

UVA Health lung researchers are developing a promising approach to detecting patients at risk of interstitial lung disease (ILD), an increasingly common condition that is a leading reason for lung ...

A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...